The possible role of IL-17 in obesity-associated cancer

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 2265-2271

  Gislette, Tiphaine ^a   Chen, Jiezhong ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

IL 17; IL 6; MAPK; Obesity associated cancer; Src PI3K Akt; Stat3

Indexed keywords

ADIPONECTIN; CYCLOOXYGENASE 2; CYTOKINE; GROWTH FACTOR; INSULIN; INTERLEUKIN 17; INTERLEUKIN 6; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PROTEIN KINASE C; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANGIOGENESIS; BLADDER CANCER; BLOOD LEVEL; CANCER INCIDENCE; CELL CYCLE; CELL DIFFERENTIATION; ENZYME ACTIVATION; HUMAN; INFLAMMATION; LUNG CANCER; LYMPHANGIOGENESIS; MELANOMA; NEOPLASM; NONHUMAN; OBESITY; OVARY CANCER; PROTEIN EXPRESSION; RISK FACTOR; SHORT SURVEY; SIGNAL TRANSDUCTION; WART VIRUS;

ANIMALS; HUMANS; INTERLEUKIN-17; MICE; MICE, KNOCKOUT; NEOPLASMS; OBESITY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 78650270277     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.212     Document Type: Short Survey

References (65)

1. Obesity in the United States: http://en.wikipedia.org/wiki/Obesity-in- the-United-States. Accessed on October 15, 2010.
2. Calle, E.E. and Kaaks, R. (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4(8), 579-591.
3. Huang, X.F. and Chen, J. (2009) Obesity, the PI3K/Akt signal pathway and colon cancer. Obes. Rev. 10(6), 610-616.
4. Sumarac-Dumanovic, M. et al. (2009) Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int. J. Obes. (Lond.) 33(1), 151-156.
5. Winer, S. et al. (2009) Obesity predisposes to Th17 bias. Eur. J. Immunol. 39(9), 2629-2635.
6. Weaver, C.T. et al. (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25, 821-852.
7. Xu, S. and Cao, X. (2010) Interleukin-17 and its expanding biological functions. Cell. Mol. Immunol. 7(3), 164-174.
8. Khader, S.A. et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8(4), 369-377.
9. Wu, X. et al. (2010) Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int. J. Cancer 127(1), 86-92.
10. Martin-Orozco, N. et al. (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5), 787-798.
11. Zou, W. and Restifo, N.P. (2010) T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10(4), 248-256.
12. Murugaiyan, G. and Saha, B. (2009) Protumor vs antitumor functions of IL-17. J. Immunol. 183(7), 4169-4175.
13. Fenton, J.I. and Birmingham, J.M. (2010) Adipokine regulation of colon cancer: adiponectin attenuates interleukin- 6-induced colon carcinoma cell proliferation via STAT-3. Mol. Carcinog. 49(7), 700-709.
14. Chen, J. (2010) The IL-23/IL-17 axis may be important in obesity-associated cancer by way of the activation of multiple signal pathways. Int. J. Obes. (Lond.) 34(7), 1227-1228; author reply 1229.
15. Pini, M. and Fantuzzi, G. (2009) Enhanced production of IL-17A during zymosan-induced peritonitis in obese mice. J. Leukoc. Biol. 87(1), 51-58.
16. Bettelli, E. et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090), 235-238.
17. Volpe, E. et al. (2008) A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 9(6), 650-657.
18. Chen, Z. and O'Shea, J.J. (2008) Th17 cells: a new fate for differentiating helper T cells. Immunol. Res. 41(2), 87-102.
19. Shin, J.H., Shin, D.W., and Noh, M. (2009) Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes. Biochem. Pharmacol. 77(12), 1835-1844.
20. Kehlen, A. et al. (1999) Interleukin-17 stimulates the expression of IkappaB alpha mRNA and the secretion of IL-6 and IL-8 in glioblastoma cell lines. J. Neuroimmunol. 101(1), 1-6.
21. Gaffen, S.L. (2009) Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9(8), 556-567.
22. Fossiez, F. et al. (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183(6), 2593-2603.
23. Chen, Z. et al. (2007) Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 56(9), 2936-2946.
24. Charles, K.A. et al. (2009) The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J. Clin. Invest. 119(10), 3011-3023.
25. Numasaki, M. et al. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood. 101(7), 2620-2627.
26. Wu, S. et al. (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15(9), 1016-1022.
27. Prabhala, R.H. et al. (2010) Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115(26), 5385-5392.
28. Chen, X. et al. (2010) Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 69(3), 348-354.
29. Hwang, J.J., Ghobrial, I.M., and Anderson, K.C. (2006) New frontiers in the treatment of multiple myeloma. TheScientificWorldJOURNAL 6, 1475-1503.
30. Chen, J. and McMillan, N.A.J. (2007) Multiple signal pathways in the leukemogenesis and therapeutic implications. Leuk. Res. 31(12), 1759-1760.
31. Chen, J. (20080 Is Src the key to understanding metastasis and developing new treatments for colon cancer? Nat. Clin. Pract. Gastroenterol. Hepatol. 5(6), 306-307.
32. Huveneers, S. and Danen, E.H. (2010) The interaction of SRC kinase with beta3 integrin tails: a potential therapeutic target in thrombosis and cancer. TheScientificWorldJOURNAL 10, 1100-1105.
33. Yu, H., Pardoll, D., and Jove, R. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9(11), 798-809.
34. Shalom-Barak, T., Quach, J., and Lotz, M. (1998) Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J. Biol. Chem. 273(42), 27467-27473.
35. Radosavljevic, G. et al. (2010) Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 57(2), 135-144.
36. Gomez-Cambronero, J. (2010) New concepts in phospholipase D signaling in inflammation and cancer. TheScientificWorldJOURNAL 10, 1356-1369.
37. Chang, Y.H. et al. (2010) Up-regulation of interleukin-17 expression by human papillomavirus type 16 E6 in nonsmall cell lung cancer. Cancer 116(20), 4800-4809.
38. Iyoda, K. et al. (2003) Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 97(12), 3017-3026.
39. Laan, M. et al. (2001) IL-17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogenactivated protein (MAP) kinases. Br. J. Pharmacol. 133(1), 200-206.
40. Puddicombe, S.M. and Davies, D.E. (2000) The role of MAP kinases in intracellular signal transduction in bronchial epithelium. Clin. Exp. Allergy 30(1), 7-11.
41. Wilkinson, M.G. and Millar, J.B. (2000) Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J. 14(14), 2147-2157.
42. Hsieh, H.G., Loong, C.C., and Lin, C.Y. (2002) Interleukin-17 induces src/MAPK cascades activation in human renal epithelial cells. Cytokine 19(4), 159-174.
43. Iyoda, M. et al. (2010) IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1beta. Am. J. Physiol. Renal Physiol. 298(3), F779-787.
44. Kleine-Lowinski, K. et al. (2003) Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int. J. Cancer 107(3), 407-415.
45. Kleine-Lowinski, K. et al. (1999) Monocyte-chemo-attractant-protein-1 (MCP-1)-gene expression in cervical intraepithelial neoplasias and cervical carcinomas. Int. J. Cancer 82(1), 6-11.
46. Rahman, M.S. et al. (2006) IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2, JNK, and p38) pathways. J. Immunol. 177(6), 4064-4071.
47. Kao, C.Y. et al. (2004) IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J. Immunol. 173(5), 3482-3491.
48. Jiang, Z. et al. (2009) MOG(35-55) i.v suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways. Eur. J. Immunol. 39(3), 789-799.
49. Subramaniam, S.V., Cooper, R.S., and Adunyah, S.E. (1999) Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Biochem. Biophys. Res. Commun. 262(1), 14-19.
50. Wang, L. et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206(7), 1457-1464.
51. Kovacs, E. (2010) Investigation of the proliferation, apoptosis/necrosis, and cell cycle phases in several human multiple myeloma cell lines. Comparison of Viscum album QuFrF extract with vincristine in an in vitro model. TheScientificWorldJOURNAL 10, 311-320.
52. Yin, Z.J. et al. (2010) Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. J. Surg. Res. [Epub ahead of print]
53. Harris, T.J. et al. (2007) Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol. 179(7), 4313-4317.
54. You, Q.H. et al. (2010) Interleukin-17F-induced pulmonary microvascular endothelial monolayer hyperpermeability via the protein kinase C pathway. J. Surg. Res. 162(1), 110-121.
55. Gelman, I.H. et al. (1998) Control of cytoskeletal architecture by the src-suppressed C kinase substrate, SSeCKS. Cell Motil. Cytoskeleton 41(1), 1-17.
56. Hymowitz, S.G. et al. (2001) IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 20(19), 5332-5341.
57. Starnes, T. et al. (2001) Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J. Immunol. 167(8), 4137-4140. (Pubitemid 32954284)
58. Jakobsson, L. and Claesson-Welsh, L. (2008) Vascular basement membrane components in angiogenesis - an act of balance. TheScientificWorldJOURNAL 8, 1246-1249.
59. He, D. et al. (2010) IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J. Immunol. 184(5), 2281-2288.
60. Wakita, D. et al. (2010) Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 40(7), 1927-1937.
61. Silva-Santos, B. (2010) Promoting angiogenesis within the tumor microenvironment: the secret life of murine lymphoid IL-17-producing gammadelta T cells. Eur. J. Immunol. 40(7), 1873-1876.
62. Gnerlich, J.L. et al. (2010) Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J. Immunol. 185(7), 4063-4071.
63. Kryczek, I. et al. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114(6), 1141-1149.
64. Maniati, E., Soper, R., and Hagemann, T. (2010) Up for mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 29(42), 5653-5662.
65. Chae, W.J. et al. (2010) Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 107(12), 5540-5544.